ApolipoproteinE and Alzheimer's disease: A genetic, molecular and neuroimaging review

Canadian Journal of Neurological Sciences

Volumn 26, Issue 2, 1999, Pages 77-88

  Swartz, R H ^a   Black, S E ^a   St George Hyslop, P ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMYLOID; APOLIPOPROTEIN E;

ALZHEIMER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; GENE ISOLATION; GENE MUTATION; GENETIC RISK; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LIPOPROTEIN METABOLISM; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AGED; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; GENETIC MARKER; GENETICS; PATHOPHYSIOLOGY; SCINTISCANNING; SEX DIFFERENCE; TEMPORAL LOBE;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FEMALE; GENETIC MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; SEX FACTORS; TEMPORAL LOBE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032587772     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (190)

1. Black SE. Focal cortical atrophy syndromes. Brain and Cognition 1996; 31: 188-229.
2. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42: 1097-1105.
3. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994; 150: 899-913.
4. Ebly EM, Parhad IM, Hogan DB, Fung TS. Prevalence and types of dementia in the very old: results from the Canadian Study of Health and Aging. Neurology 1994; 44: 1593-1600.
5. Ostbye T, Crosse E. Net economic costs of dementia in Canada. Can Med Assoc J 1994; 151: 1457-1464.
6. Canadian Study of Health and Aging Working Group. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology 1994; 44: 2073-2080.
7. Ott A, Slooter AJ, Hofman A, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998; 351: 1840-1843.
8. Breitner JC, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16: 523-530.
9. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-432.
10. Birge SJ. The role of estrogen in the treatment of Alzheimer's disease. Neurology 1997; 48 (Suppl. 7): S36-S41.
11. Marz W, Scharnagl H, Kirca M, et al. Apolipoprotein E polymorphism is associated with both senile plaque load and Alzheimer-type neurofibrillary tangle formation. Ann NY Acad Sci 1996; 777: 276-280.
12. Gearing M, Mirra SS, Hedreen JC, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995; 45: 461-466.
13. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
14. Hyman, BT. New Neuropathological criteria for Alzheimer disease. Arch Neurol 1998; 55: 1174-1176.
15. Funato H, Yoshimura M, Kusui K, et al. Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. Am J Pathol 1998; 152: 1633-1640.
16. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997; 275: 630-631.
17. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995; 92: 4725-4727.
18. Hyman BT, West HL, Rebeck GW, et al. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci USA 1995; 92: 3586-3590.
19. Ma J, Yee A, Brewer HB, Jr., Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994; 372: 92-94.
20. Hyman BT, Van Horsen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984; 225: 1168-1170.
21. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997; 41: 17-24.
22. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996; 39: 62-70.
23. Caramelli P, Robitaille Y, Cholette AL, et al. Clinicopathological study in Alzheimer's disease: senile plaques correlate with profiles of cognitive impairment. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM, eds. Alzheimer's Disease: Biology, Diagnosis and Therapeutics. Chichester: John Wiley & Sons Ltd., 1997: 267-274.
24. Braak H, Braak E. Alzheimer neuropathology and limbic circuits. In: Vogt BA, Gabriel M, eds. Neurobiology of Cingulate Cortex and Limbic Thalamus: a Comprehensive Handbook. Boston: Birkhauser, 1993: 606-626.
25. Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993; 33: 403-408.
26. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-284.
27. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
28. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990; 27: 457-464.
29. Brun A, Gustafson L. Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study. Arch Psychiat Nervenkr 1976; 223: 15-33.
30. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-126.
31. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1981; 215: 1237-1239.
32. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
33. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-1230.
34. Rogers SL, Friedhoff LT. Long-term efficacy and safety of denepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open label extension study. Eur Neuropsychopharmacol 1998; 8(1): 67-75.
35. Simpkins JW, Green PS, Gridley KE, et al. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease. Am J Med 1997; 103: 19S-25S.
36. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996; 46: 1580-1584.
37. Henderson VW. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 1997; 48 (Suppl. 7): S27-S35.
38. Marcusson J, Rother M, Kittner B, et al. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord 1997; 8: 320-328.
39. Rossor MN, Fox NC, Freeborough PA, Harvey RJ. Clinical features of sporadic and familial Alzheimer's disease. Neurodegeneration 1996; 5: 393-397.
40. Nagy Z, Jobst KA, Esiri MM, et al. Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria. Dementia 1996; 7: 76-81.
41. Nagy Z, Esiri MM, Jobst KA, et al. Clustering of pathological features in Alzheimer's disease: clinical and neuroanatomical aspects. Dementia 1996; 7: 121-127.
42. Nagy Z, Esiri MM, Jobst KA, et al. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 1995; 6: 21-31.
43. Ohm TG, Muller H, Braak H, Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience 1995; 64: 209-217.
44. Bird TD. Clinical genetics of familial alzheimer's disease. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer Disease. New York: Raven Press Ltd., 1994: 65-74.
45. Holder JL, Habbak RA, Pearlson GD, et al. Reduced survival of apolipoprotein E4 homozygotes in Down's syndrome? Neuroreport 1996; 7: 2455-2456.
46. Lendon CL, Ashall F, Goate AM. Exploring the etiology of Alzheimer disease using molecular genetics. JAMA 1997; 277: 825-831.
47. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7: 180-184.
48. Sherrington R, Froelich S, Sorbi S, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 1996; 5: 985-988.
49. Kamino K, Sato S, Sakaki Y, et al. Three different mutations of presenilin 1 gene in early-onset Alzheimer's disease families. Neurosci Lett 1996; 208: 195-198.
50. Murphy GM, Jr., Forno LS, Ellis WG, et al. Antibodies to presenilin proteins detect neurofibrillary tangles in Alzheimer's disease. Am J Pathol 1996; 149: 1839-1846.
51. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995; 92: 12260-12264.
52. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994; 17: 525-530.
53. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342: 697-699.
54. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
55. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
56. Hyman BT, Gomez-Isla T, West H, et al. Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease. Window on molecular epidemiology. Ann NY Acad Sci 1996; 777: 158-165.
57. Hyman BT, Gomez-Isla T, Rebeck GW, et al. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. Ann NY Acad Sci 1996; 802: 1-5.
58. Duara R, Barker WW, Lopez-Alberola R, et al. Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Neurology 1996; 46: 1575-1579.
59. West HL, Rebeck GW, Hyman BT. Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. Neurosci Lett 1994; 175: 46-48.
60. Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology 1996; 46: 673-677.
61. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Ann Rev Med 1996; 47: 387-400.
62. Nalbantoglu J, Gilfix BM, Bertrand P, et al. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Ann Neurol 1994; 36: 889-895.
63. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977-1981.
64. Bickeboller H, Campion D, Brice A, et al. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet 1997; 60: 439-446.
65. Tang MX, Maestre G, Tsai WY, et al. Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet 1996; 58: 574-584.
66. Locke PA, Conneally PM, Tanzi RE, Gusella JF, Haines JL. Apolipoprotein E4 allele and Alzheimer disease: examination of allelic association and effect on age at onset in both early- and late-onset cases. Genet Epidemiol 1995; 12: 83-92.
67. Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol 1993; 34: 752-754.
68. Brousseau T, Legrain S, Berr C, et al. Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology 1994; 44: 342-344.
69. Peacock ML, Fink JK. ApoE epsilon 4 allelic association with Alzheimer's disease: independent confirmation using denaturing gradient gel electrophoresis. Neurology 1994; 44: 339-341.
70. Tsai MS, Tangalos EG, Petersen RC, et al. Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet 1994; 54: 643-649.
71. Richey PL, Siedlak SL, Smith MA, Perry G. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Biochem Biophys Res Commun 1995; 208: 657-663.
72. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 8098-8102.
73. Yamaguchi H, Ishiguro K, Sugihara S, et al. Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer beta-amyloid deposition. Acta Neuropathol (Berl) 1994; 88: 413-419.
74. Sheng JG, Mrak RE, Griffin WS. Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression. Neuropathol Appl Neurobiol 1996; 22: 334-341.
75. Holtzman DM, Pitas RE, Kilbridge J, et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neunte outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci USA 1995; 92: 9480-9484.
76. Sanan DA, Weisgraber KH, Russell SJ, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994; 94: 860-869.
77. LaDu MJ, Falduto MT, Manelli AM, et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 1994; 269: 23403-23406.
78. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 9649-9653.
79. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995; 333: 1242-1247.
80. Nagy Z, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995; 69: 757-761.
81. Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT, Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA 1995; 92: 763-767.
82. Zhou Z, Smith JD, Greengard P, Gandy S. Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Mol Med 1996; 2: 175-180.
83. Pillot T, Goethals M, Vanloo B, et al. Specific modulation of the fusogenic properties of the Alzheimer beta-amyloid peptide by apolipoprotein E isoforms. Eur J Biochem 1997; 243: 650-659.
84. Han SH, Einstein G, Weisgraber KH, et al. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J Neuropathol Exp Neurol 1994; 53: 535-544.
85. Han SH, Hulette C, Saunders AM, et al. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp Neurol 1994; 128: 13-26.
86. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neurosci Lett 1996; 214: 163-166.
87. Strittmatter WJ, Saunders AM, Goedert M, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA 1994; 91: 11183-11186.
88. Huang DY, Goedert M, Jakes R, et al. Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. Neurosci Lett 1994; 182: 55-58.
89. Lindh M, Blomberg M, Jensen M, et al. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett 1997; 229: 85-88.
90. Arai H, Higuchi S, Sasaki H. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Gerontology 1997; 43 (Suppl 1): 2-10.
91. Craft S, Peskind E, Schwartz MW, et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998; 50: 164-168.
92. Masliah E, Mallory M, Veinbergs I, Miller A, Samuel W. Alterations in apolipoprotein E expression during aging and neurodegeneration. Prog Neurobiol 1996; 50: 493-503.
93. Nathan B, Bellosta S, Sanan DA, et al. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994; 264: 850-852.
94. Soininen HS, Riekkinen PJ, Sr. Apolipoprotein E, memory and Alzheimer's disease. Trends Neurosci 1996; 19: 224-228.
95. Chen Y, Lomnitski L, Michaelson DM, Shohami E. Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience 1997; 80: 1255-1262.
96. Chapman S, Michaelson DM. Specific neurochemical derangements of brain projecting neurons in apolipoprotein E-deficient mice. J Neurochem 1998; 70: 708-714.
97. Ohm TG, Kirca M, Bohl J, et al. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995; 66: 583-587.
98. Soininen H, Lehtovirta M, Helisalmi S, et al. Increased acetylcholinesterase activity in the CSF of Alzheimer patients carrying apolipoprotein epsilon4 allele. Neuroreport 1995; 6: 2518-2520.
99. Soininen H, Kosunen O, Helisalmi S, et al. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. Neurosci Lett 1995; 187: 79-82.
100. Iyo M, Namba H, Fukushi K, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997; 349: 1805-1809.
101. Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann NY Acad Sci 1996; 802: 101-110.
102. Svensson AL, Warpman U, Hellstrom-Lindahl E, et al. Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Neurosci Lett 1997; 232: 37-40.
103. Corey-Bloom J, Tiraboachi P, Sabbagh MN, et al. Apolipoprotein genotype does not predict choline acetyltransferase activity or synaptic loss in Alzheimer's disease. Neurology 1998; 50 (Suppl. 4): A60-A61.
104. Lippa CF, Smith TW, Saunders AM, et al. Apolipoprotein E genotype and Lewy body disease. Neurology 1995; 45: 97-103.
105. Egensperger R, Bancher C, Kosel S, et al. The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. Biochem Biophys Res Commun 1996; 224: 484-486.
106. Marder K, Maestre G, Cote L, et al. The apolipoprotein epsilon 4 allele in Parkinson's disease with and without dementia. Neurology 1994; 44: 1330-1331.
107. Lyketsos CG, Baker L, Warren A, et al. Depression, delusions, and hallucinations in Alzheimer's disease: no relationship to apolipoprotein E genotype. J Neuropsychiatry Clin Neurosci 1997; 9: 64-67.
108. Treves TA, Bornstein NM, Chapman J, et al. APOE-epsilon 4 in patients with Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1996; 10: 189-191.
109. Slooter AJ, Tang MX, van Duijn CM, et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA 1997; 277: 818-821.
110. Skoog I, Hesse C, Aevarsson O, et al. A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry 1998; 64: 37-43.
111. Tang MX, Maestre G, Tsai WY, et al. Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer's disease. Ann NY Acad Sci 1996; 802: 6-15.
112. Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995; 45: 555-557.
113. O'Meara ES, Kukull WA, Sheppard L, et al. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. Am J Epidemiol 1997; 146: 373-384.
114. Schupf N, Kapell D, Lee JH, et al. Onset of dementia is associated with apolipoprotein E epsilon4 in Down's syndrome. Ann Neurol 1996; 40: 799-801.
115. Lin WR, Shang D, Itzhaki RF. Neurotropic viruses and Alzheimer disease. Interaction of herpes simplex type 1 virus and apolipoprotein E in the etiology of the disease. Mol Chem Neuropathol 1996; 28: 135-141.
116. Itzhaki RF, Lin WR, Shang D, et al. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 1997; 349: 241-244.
117. Albert SM, Gurland B, Maestre G, et al. APOE genotype influences functional status among elderly without dementia. Am J Med Genet 1995; 60: 583-587.
118. Reed T, Carmelli D, Swan GE, et al. Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. Arch Neurol 1994; 51: 1189-1192.
119. Blesa R, Adroer R, Santacruz P, et al. High apolipoprotein E epsilon 4 allele frequency in age-related memory decline. Ann Neurol 1996; 39: 548-551.
120. Yaffe K, Cauley J, Sands L, Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol 1997; 54: 1110-1114.
121. Kuller LH, Shemanski L, Manolio T. et al. Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke 1998; 29: 388-398.
122. Bondi MW, Salmon DP, Monsch AU, et al. Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology 1995; 45: 2203-2206.
123. Kidron D, Black SE, Stanchev P, et al. Quantitative MR volumetry in Alzheimer's disease - topographic markers and the effects of sex and education. Neurology 1997; 49: 1504-1512.
124. Ichise M, Ballinger JR, Golan H, et al. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF-SPECT. J Nucl Med 1996; 37: 513-520.
125. Ryding E. SPECT measurements of brain function in dementia; a review. Acta Neurol Scand Suppl 1996; 168: 54-58.
126. Nordberg A. Application of PET in dementia disorders. Acta Neurol Scand Suppl 1996; 168: 71-76.
127. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995; 273: 942-947.
128. Lehtovirta M, Soininen H, Laakso MP, et al. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry 1996; 60: 644-649.
129. Bonte FJ, Weiner MF, Bigio EH, White CL3. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 1997; 202: 793-797.
130. Johnson KA, Jones K, Holman BL, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998; 50: 1563-1571.
131. Wahlund LO. Magnetic resonance imaging and computed tomography in Alzheimer's disease. Acta Neurol Scand Suppl 1996; 168: 50-53.
132. Pantel J, Schroder J, Schad LR, et al. Quantitative magnetic resonance imaging and neuropsychological functions in dementia of the Alzheimer type. Psychol Med 1997; 27: 221-229.
133. Jack CR, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49: 786-794.
134. Smith AD, Jobst KA. Use of structural imaging to study the progression of Alzheimer's disease. Br Med Bull 1996; 52: 575-586.
135. Jobst KA, Smith AD, Szatmari M, et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet 1994; 343: 829-830.
136. Jobst KA, Hindley NJ, King E, Smith AD. The diagnosis of Alzheimer's disease: a question of image?. J Clin Psychiatry 1994; 55 (Suppl.): 22-31.
137. Jack Jr. CR, Petersen RC, Xu YC, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol 1998; 43(3): 303-310.
138. Small GW, Komo S, La Rue A, et al. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann NY Acad Sci 1996; 802: 70-78.
139. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752-758.
140. Corder EH, Jelic V, Basun H, et al. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Arch Neurol 1997; 54: 273-277.
141. Lehtovirta M, Kuikka J, Helisalmi S, et al. Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry 1998; 64: 742-746.
142. Swartz RH, Black SE, Leibovitch FS, et al. Sex and mental status, but not apolipoprotein E, correlate with parietal and temporal hypoperfusion on SPECT in Alzheimer's disease. Neurology 1998; 50 (Suppl. 4): A159.
143. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoproiein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273: 1274-1278.
144. Frisoni GB, Govoni S, Geroldi C, et al. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 1995; 37: 596-604.
145. Stern Y, Brandt J, Albert M, et al. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997; 41: 615-620.
146. Kurz A, Egensperger R, Haupt M, et al. Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 1996; 47: 440-443.
147. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996; 47: 444-448.
148. Asada T, Kariya T, Yamagata Z, Kinoshita T, Asaka A. ApoE epsilon 4 allele and cognitive decline in patients with Aizheimer's disease. Neurology 1996; 47: 603.
149. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996; 46: 149-154.
150. Murphy GM, Jr., Taylor J, Kraemer HC, Yesavage J, Tinklenberg JR. No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. Am J Psychiatry 1997; 154: 603-608.
151. Dal Fomo G, Rasmusson DX, Brandt J, et al. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol 1996; 53: 345-350.
152. Corder EH, Lannfelt L, Basun H. Apolipoprotein E genotype and the rate of decline in probable Alzheimer disease [letter; comment]. Arch Neurol 1996; 53: 1094-1095.
153. Blacker D, Haines JL, Rodes L, et al. ApoE-4 and age at onset of Alzheimer's disease: The NIMH Genetics Initiative. Neurology 1997; 48: 139-147.
154. Payami H, Grimslid H, Oken B, et al. A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype. Am J Hum Genet 1997; 60: 948-956.
155. Plassman BL, Breitner JC. Apolipoprotein E and cognitive decline in Alzheimer's disease. Neurology 1996; 47: 317-320.
156. Mortimer JA. Brain reserve and the clinical expression of Alzheimer's disease. Geriatrics 1997; 52: S50-S53.
157. Payami H, Zareparsi S, Montee KR, et al. Gender difference in apolipoprotein E - associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet 1996; 58: 803-811.
158. Rao VS, Cupples A, van Duijn CM, et al. Evidence for major gene inheritance of Alzheimer disease in families of patients with and without apolipoprolein E epsilon 4. Am J Hum Genet 1996; 59: 664-675.
159. Corder EH, Saunders AM, Strittmatter WJ, et al. The apolipoprotein E E4 allele and sex-specific risk of Alzheimer's disease. JAMA 1995; 273: 373-374.
160. Adroer R, Santacruz P, Blesa R, et al. Apolipoprotein E4 allele frequency in Spanish Alzheimer and control cases. Neurosci Lett 1995; 189: 182-186.
161. Yamagata Z, Asada T, Kinoshita A, Zhang Y, Asaka A. Distribution of apolipoprotein E gene polymorphisms in Japanese patients with Alzheimer's disease and in Japanese centenarians. Human Heredity 1997; 47: 22-26.
162. Katzman R, Zhang MY, Chen PJ, et al. Effects of apolipoprotein E on dementia and aging in the Shanghai Survey of Dementia. Neurology 1997; 49: 779-785.
163. Hendrie HC, Hall KS, Hui S, et al. Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Ann Neurol 1995; 37: 118-120.
164. Rosenberg RN, Richter RW, Risser RC, et al. Genetic factors for the development of Alzheimer disease in the Cherokee Indian. Arch Neurol 1996; 53: 997-1000.
165. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease - a meta-analysis. JAMA 1997; 278: 1349-1356.
166. Sahota A, Yang M, Gao S, et al. Apolipoprotein E-associated risk for Alzheimer's disease in the African-American population is genotype dependent. Ann Neurol 1997; 42: 659-661.
167. Maestre G, Ottman R, Stern Y, et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol 1995; 37: 254-259.
168. Talbot C, Lendon C, Craddock N, et al. Protection against Alzheimer's disease with apoE epsilon 2. Lancet 1994; 343: 1432-1433.
169. Brayne C, Harrington CR, Wischik CM, et al. Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. Dementia 1996; 7: 169-174.
170. Lippa CF, Smith TW, Saunders AM, et al. Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology 1997; 48: 515-519.
171. van Duijn CM, de Knijff P, Wehnert A, et al. The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol 1995; 37: 605-610.
172. Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Arch Neurol 1995; 52: 1074-1079.
173. Evans DA, Beckett LA, Field TS, et al. Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA 1997; 277: 822-824.
174. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996; 46: 661-665.
175. Roses AD. Apolipoprotein E and Alzheimer's disease. A rapidly expanding field with medical and epidemiological consequences. Ann NY Acad Sci 1996; 802: 50-57.
176. Relkin NR, Kwon YJ, Tsai J, Gandy S. The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease. Ann NY Acad Sci 1996; 802: 149-176.
177. Roses AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol 1995; 38: 6-14.
178. Roses AD, Saunders AM. Prediction for unimpaired subjects is different from diagnosis of demented patients. Ann Neurol 1997; 41: 414-416.
179. Welsh-Bohmer KA, Gearing M, Saunders AM, Roses AD, Mirra S. Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer's Disease. Ann Neurol 1997; 42: 319-325.
180. Roses AD. Genetic testing for Alzheimer disease - practical and ethical issues. Arch Neurol 1997; 54: 1226-1229.
181. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998; 338: 506-511.
182. Lavenu J, Pasquier F, Lebert F, Jacob B, Petit H. Association between medial temporal lobe atrophy on CT and parietotemporal uptake decrease on SPECT in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1997; 63: 441-445.
183. Anonymous. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. JAMA 1995; 274: 1627-1629.
184. Post SG, Whitehouse PJ, Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA 1997; 277: 832-836.
185. Mayeux R, Schupf N. Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine. Am J Public Health 1995; 85: 1280-1284.
186. Anonymous. Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group. Lancet 1996; 347: 1091-1095.
187. Frisoni GB, Manfredi M, Geroldi C, et al. The prevalence of apoE-epsilon4 in Alzheimer's disease is age dependent. J Neurol Neurosurg Psychiatry 1998; 65: 103-106.
188. Pirttila T, Soininen H, Mehta PD, et al. Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains. Neurobiol Aging 1997; 18: 121-127.
189. Pericak-Vance MA, Bass MP, Yamaoka LH, et al. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA 1997; 278: 1237-1241.
190. Reisberg B. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiat 1982; 139: 1136-1139.